Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Poster Submissions Invited For PAC - Pharmaceutical Society Of Australia
A major feature of the annual Pharmacy Australia Congress is the Poster Session which

Blogs Comment On Supreme Court Pregnancy Leave Ruling, Obama's Notre Dame Speech, Other Topics
The following summarizes selected women"s health-related blog entries. ~ "Peaceful Revolution: Another Blow to Women," Debra Ness, Huffington Post blogs: The Supreme Court"s ruling this week in AT&T Corp. v. Hulteen "dealt a serious and painful blow to working women and the families who rely on their retirement benefits," Ness, president of the National Partnership for Women and Families, writes. The ruling "affects a limited number of people," and it "would be easy to ignore them -- easy, but terribly wrong," Ness continues. "This ruling sends a terrible message about whether discrimination will bring penalties and costs, and whether the courts will address the ongoing effects of prior discrimination," she writes. Ness notes that the ruling "couldn"t come at a worse time," adding, "In today"s grim economic climate, women and their families cannot afford to see their retirement benefits kept lower by discriminatory workplace policies that should have been remedied decades ago." Ness writes that it is "sobering that, at a time when negative stereotypes about pregnant women clearly persist, we have a Supreme Court that doesn"t stand firm for equal rights and equal opportunity." She concludes, "It"s a good reminder of what"s at stake with the Supreme Court nomination President Obama is about to make" (Ness, Huffington Post blogs, 5/21).~ "This Week in Religion and Politics," Sarah Posner, American Prospect"s "The FundamentaList": When "viewed in the context of Obama"s entire faith-based outreach project, the events" surrounding the University of Notre Dame"s commencement ceremony "highlighted how he has embraced traditionalist, conservative religion -- to the detriment of sexual and reproductive justice," Posner writes. President Obama has "focused his outreach efforts" to reduce the need for abortion "on more conservative religious groups" and "claims to honor their position on moral issues," Posner writes. However, "when the dust settles on the Notre Dame controversy, he"ll have to figure out what to do with the policy advice he has sought" from the White House Office on Faith-Based and Neighborhood Partnerships, she continues. Posner adds, "How Obama reacts to that advice will demonstrate whether the council is mere window dressing to shore up support from swing constituencies or whether Obama will yield to conservative religious dogma on reproductive-health issues." Meanwhile, Christian conservatives have been "making hay of the findings" of recent Pew and Gallup polls that found more U.S. residents identifying with "pro-life" positions and using the data to argue "that Obama"s position is out of touch with the majority of Americans," Posner writes. However, as bloggers at The Monkey Cage and FiveThirtyEight have pointed out, the polls are not representative of most U.S. residents" views on abortion rights, she writes. "Because of that deception on reproductive rights, it"s more important than ever for the president to lay the moral groundwork for his own position -- not just to recognize the moral qualms of abortion opponents," Posner says (Posner, "The FundamentaList," American Prospect, 5/20).~ "Meghan McCain Preaches What She Practices," Willa Paskin, Slate"s "XX Factor": Meghan McCain -- Sen. John McCain"s (R-Ariz.) daughter -- "acquitted herself quite admirably" on Monday"s episode of Comedy Central"s "The Colbert Report" by "defending her core position" that the Republican Party "needs to appeal to younger voters, and it can only do so by getting liberal on social issues," Paskin writes. On the show, McCain said, "I think it"s not realistic for this generation to be just plain abstinent, I think we need to have sex education with condoms and birth control. ... I would never practice anything I didn"t preach." Paskin also includes a video clip of McCain"s appearance (Paskin, "XX Factor," Slate, 5/19).~ "Skill the Messenger," Cristina Page, Birth Control Watch: Alaska Gov. Sarah Palin"s (R) 18-year-old daughter Bristol -- who was
News of the day
Medicine Use Reviews To Get First National Audit
The nation"s first online audit of Medicines Use Reviews (MURs) is being launched tomorrow
Diagnostics

Bioheart Announces Acceptance Of Marvel-1 Data For Presentation At The Heart Failure Society Of America (HFSA) Meeting

Bioheart, Inc. (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today acceptance of MARVEL-1 data for presentation at the Heart Failure Society of America (HFSA) Meeting September 13-16th, 2009 in Boston, Massachusetts. Chris O"Connor, MD, Head of Heart Failure at Duke University and Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University will present the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session on September 16, 2009. Doug Owens, RN, MPH, CCRA, Director of Clinical and Regulatory Affairs, at Bioheart, Inc., states "We are very excited about the positive results we have seen in the Marvel-Part 1 study and look forward to presenting the final data. We are eager to launch part two of the MARVEL Study and anticipate rapid enrollment upon re-initiation of the trial." Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient"s quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell((R)), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient"s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company"s pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell((R)) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. MyoCell, MyoCell SDF-1 and MyoCath are trademarks of Bioheart, Inc. Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008; June 30, 2008 and September 30, 2008. Bioheart, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009